EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

A National Danish Effectiveness Study of Ocrelizumab Versus Natalizumab in Multiple Sclerosis

Camilla Maersk-Moller iD, Luigi Pontieri iD, Morten Leif Munding Stilund, Jeppe Romme Christensen iD, Lars Kristian Storr, Victoria Hansen, Jakob Schäfer iD, Arkadiusz Weglewski, Katerina Quinto Romani, Henrik Boye Jensen iD, Zsolt Illes, Victoria Papp und 7 weitere

European Journal of Neurology · 2026

DOI: 10.1111/ene.70507 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Neurology, 2026. Verfasst von Camilla Maersk-Moller und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Multiple Sclerosis Clinic, Aarhus University Hospital, Aarhus N, Denmark. Hauptthemen laut MEDLINE: Natalizumab, Antibodies, Monoclonal, Humanized, Multiple Sclerosis, Relapsing-Remitting, Immunologic Factors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Scleroseforeningens Forskningspulje.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ocrelizumab and natalizumab are highly effective disease‐modifying treatments for relapsing–remitting multiple sclerosis (RRMS). Direct comparison of effectiveness is crucial for optimizing treatment decisions and improving patient outcomes. The aim was to compare any difference in effectiveness of ocrelizumab and natalizumab on disease activity and progression in RRMS.

Methods

This was a national multicenter comparative effectiveness research study using data from the nationwide population‐based registry of MS cases in Denmark. Patients were included from January 2018 to April 2023 with a history of RRMS treated with ocrelizumab or natalizumab. Inverse probability of treatment weighting based on propensity scores was applied. Main outcomes were the comparison of annualized relapse rate (ARR), time to first progression independent of relapse activity (PIRA), and time to first occurrence of new/enlarging T2 or contrast‐enhancing lesions on cerebral MRI scans.

Results

We found no statistically significant differences in the ARR between ocrelizumab‐treated ( n = 542) and natalizumab‐treated ( n = 384) patients (mean [95% CI] ARR of 0.071 [0.057–0.088] and 0.071 [0.054–0.092], respectively) and in the ARR ratio (0.996, 95% CI [0.687–1.444], p = 0.983). Similarly, we did not find differences between the two groups in terms of time to first PIRA (HR, 1.34; 95% CI, 0.88–2.02; p = 0.17) and time to first inflammatory activity in MRI scans (HR, 1.04; 95% CI, 0.74–1.25; p = 0.78).

Conclusions

The study could not demonstrate a difference in effectiveness of ocrelizumab and natalizumab treatment in this nationwide population‐based registry study in risk of relapses, disability progression, and MRI activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NatalizumabAntibodies, Monoclonal, HumanizedMultiple Sclerosis, Relapsing-RemittingImmunologic FactorsHumansDenmarkFemaleMaleAdultRegistriesDisease ProgressionMiddle AgedComparative Effectiveness ResearchTreatment OutcomeMagnetic Resonance Imaging

Stichwörter der Autor:innen

comparative effectiveness researchmultiple sclerosisnatalizumabneuropharmacologyocrelizumab

Substanzen

NatalizumabAntibodies, Monoclonal, HumanizedocrelizumabImmunologic Factors

Autor:innen und Institutionen

  • Department of Neurology, Multiple Sclerosis Clinic, Aarhus University Hospital, Aarhus N, Denmark.
  • Department of Biomedicine, Aarhus University, Aarhus C, Denmark.
  • Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital-Rigshospitalet Glostrup, Glostrup, Denmark.
  • Department of Neurology, Physiotherapy and Occupational Therapy, Gødstrup Hospital, Herning, Denmark.
  • NIDO, Centre for Research and Education, Gødstrup Hospital, Herning, Denmark.
  • Department of Neurology, Danish Multiple Sclerosis Center, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark.

ORCID-Profile: Camilla Maersk-Moller, Luigi Pontieri, Jeppe Romme Christensen, Jakob Schäfer, Henrik Boye Jensen, Tobias Sejbaek, Mai Bang Poulsen, Matthias Kant, Caroline Winther Torring, Finn Sellebjerg, Melinda Magyari

Förderung

  • Scleroseforeningens Forskningspulje

Zitieren

APA

Maersk-Moller, C., Pontieri, L., Stilund, M. L. M., Christensen, J. R., Storr, L. K., Hansen, V., Schäfer, J., Weglewski, A., Romani, K. Q., Jensen, H. B., Illes, Z., Papp, V., Sejbaek, T., Poulsen, M. B., Kant, M., Torring, C. W., Sellebjerg, F., Magyari, M., & DMSG Group (2026). A National Danish Effectiveness Study of Ocrelizumab Versus Natalizumab in Multiple Sclerosis. European Journal of Neurology. https://doi.org/10.1111/ene.70507

Vancouver

Maersk-Moller C, Pontieri L, Stilund MLM, Christensen JR, Storr LK, Hansen V, et al. A National Danish Effectiveness Study of Ocrelizumab Versus Natalizumab in Multiple Sclerosis. European Journal of Neurology. 2026. doi:10.1111/ene.70507

BibTeX
@article{MaerskMoller2026,
  author = {Maersk-Moller, Camilla and Pontieri, Luigi and Stilund, Morten Leif Munding and Christensen, Jeppe Romme and Storr, Lars Kristian and Hansen, Victoria and Schäfer, Jakob and Weglewski, Arkadiusz and Romani, Katerina Quinto and Jensen, Henrik Boye and Illes, Zsolt and Papp, Victoria and Sejbaek, Tobias and Poulsen, Mai Bang and Kant, Matthias and Torring, Caroline Winther and Sellebjerg, Finn and Magyari, Melinda and DMSG Group, DMSG Group},
  title = {A National Danish Effectiveness Study of Ocrelizumab Versus Natalizumab in Multiple Sclerosis},
  journal = {European Journal of Neurology},
  year = {2026},
  doi = {10.1111/ene.70507}
}
Kostenlos starten →